GlassScriptPhysician profile
Gary S Chuang
NPI 1013199868
$2,718.30
in general payments reported to CMS, 2019-2025
23 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $210 · 2021: $608 · 2022: $580 · 2023: $480 · 2024: $565 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $472.50 | 2019-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $239.73 | 2021-2025 | |
| Dermavant Sciences, INC. | $214.57 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $204.55 | 2019-2025 | Twyneo, Aklief, Nemluvio |
| Pfizer INC. | $201.20 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $150.04 | 2021-2024 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $146.19 | 2021-2023 | Tremfya |
| Almirall LLC | $137.03 | 2021-2024 | Klisyri |
| Organogenesis INC. | $125.53 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Vemlidy |
| Novartis Pharmaceuticals Corporation | $112.99 | 2021-2025 | |
| Abbvie INC. | $102.35 | 2021-2023 | Rinvoq |
| Vyne Pharmaceuticals INC. | $102.18 | 2020-2021 | |
| Incyte Corporation | $97.55 | 2021-2024 | Opzelura |
| Amgen INC. | $73.55 | 2023-2024 | Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $67.45 | 2021 | |
| Ucb, INC. | $26.27 | 2021 | |
| Dermira, INC. | $23.98 | 2020 | |
| Leo Pharma INC. | $22.55 | 2021 | |
| Icad, INC | $20.09 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.79 | 2021 | |
| Misonix INC | $17.68 | 2021 | |
| Tactile Systems Technology INC | $15.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Chuang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.